NASDAQ:CORT - Corcept Therapeutics Stock Price, Price Target & More

Corcept Therapeutics trades on the NASDAQ under the ticker symbol "CORT."

Corcept Therapeutics Incorporated (NASDAQ:CORT) announced its quarterly earnings data on Tuesday, May, 8th. The biotechnology company reported $0.19 EPS for the quarter, beating the Zacks' consensus estimate of $0.18 by $0.01. The biotechnology company earned $57.66 million during the quarter, compared to analyst estimates of $58.18 million. Corcept Therapeutics had a net margin of 75.05% and a return on equity of 46.78%. The firm's revenue for the quarter was up 108.9% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.06 earnings per share. View Corcept Therapeutics' Earnings History.

Corcept Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, August, 7th 2018. View Earnings Estimates for Corcept Therapeutics.

5 analysts have issued 1-year target prices for Corcept Therapeutics' shares. Their forecasts range from $20.00 to $32.00. On average, they anticipate Corcept Therapeutics' share price to reach $26.40 in the next year. View Analyst Ratings for Corcept Therapeutics.

Some companies that are related to Corcept Therapeutics include Genmab A/S (GNMSF), Alkermes (ALKS), SAGE Therapeutics (SAGE), Sarepta Therapeutics (SRPT), Ionis Pharmaceuticals (IONS), Dr.Reddy's Laboratories (RDY), Catalent (CTLT), Agios Pharmaceuticals (AGIO), Loxo Oncology (LOXO), United Therapeutics (UTHR), GALAPAGOS NV/S (GLPG), FibroGen (FGEN), Taro Pharmaceutical Industries (TARO), HUTCHISON CHINA/S (HCM) and Madrigal Pharmaceuticals (MDGL).

Headlines about CORT stock have been trending positive on Tuesday, according to Accern Sentiment Analysis. The research firm identifies negative and positive media coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Corcept Therapeutics earned a media sentiment score of 0.27 on Accern's scale. They also assigned media headlines about the biotechnology company an impact score of 44.75 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.

Corcept Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (11.20%), Federated Investors Inc. PA (11.01%), Dimensional Fund Advisors LP (1.37%), Northern Trust Corp (0.97%), Nexthera Capital LP (0.91%) and Russell Investments Group Ltd. (0.68%). Company insiders that own Corcept Therapeutics stock include David L Mahoney, G Leonard Baker Jr, Gary Charles Robb, James N Wilson, Joseph K Belanoff, Patrick G Enright, Renee D Gala and Robert S Fishman. View Institutional Ownership Trends for Corcept Therapeutics.

CORT stock was sold by a variety of institutional investors in the last quarter, including Prudential Financial Inc., Old Mutual Global Investors UK Ltd., Mckinley Capital Management LLC Delaware, PNC Financial Services Group Inc., Oak Ridge Investments LLC, Smith Asset Management Group LP, ClariVest Asset Management LLC and Russell Investments Group Ltd.. Company insiders that have sold Corcept Therapeutics company stock in the last year include David L Mahoney, G Leonard Baker Jr and Robert S Fishman. View Insider Buying and Selling for Corcept Therapeutics.

CORT stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Nexthera Capital LP, Dimensional Fund Advisors LP, GSA Capital Partners LLP, Timpani Capital Management LLC, ETRADE Capital Management LLC, State of Tennessee Treasury Department and Federated Investors Inc. PA. Company insiders that have bought Corcept Therapeutics stock in the last two years include Gary Charles Robb and Renee D Gala. View Insider Buying and Selling for Corcept Therapeutics.

Shares of CORT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of CORT stock can currently be purchased for approximately $16.2750.

Corcept Therapeutics has a market capitalization of $2.23 billion and generates $159.20 million in revenue each year. The biotechnology company earns $129.12 million in net income (profit) each year or $0.44 on an earnings per share basis. Corcept Therapeutics employs 136 workers across the globe.

Corcept Therapeutics' mailing address is 149 COMMONWEALTH DRIVE, MENLO PARK CA, 94025. The biotechnology company can be reached via phone at 650-688-8803 or via email at [email protected]